595 USD
-5.02 (-0.84%)
595 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to MEDP. MEDP was compared to 57 industry peers in the Life Sciences Tools & Services industry. MEDP scores excellent points on both the profitability and health parts. This is a solid base for a good stock. MEDP is growing strongly while it is still valued neutral. This is a good combination! These ratings could make MEDP a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
MEDP had positive earnings in the past year.
In the past year MEDP had a positive cash flow from operations.
Each year in the past 5 years MEDP has been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of MEDP (24.70%) is better than 100.00% of its industry peers.
Looking at the Return On Equity, with a value of 147.46%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 91.45%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MEDP is significantly above the industry average of 14.00%.
The 3 year average ROIC (38.75%) for MEDP is below the current ROIC(91.45%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
With an excellent Profit Margin value of 18.36%, MEDP belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
MEDP's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 21.50%, MEDP belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
In the last couple of years the Operating Margin of MEDP has grown nicely.
The Gross Margin of MEDP (31.11%) is worse than 70.18% of its industry peers.
MEDP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
Compared to 1 year ago, MEDP has less shares outstanding
Compared to 5 years ago, MEDP has less shares outstanding
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MEDP has an Altman-Z score of 8.40. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.40, MEDP belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.4 |
ROIC/WACC8.36
WACC10.94%
2.3 Liquidity
MEDP has a Current Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP has a Current ratio of 0.57. This is amonst the worse of the industry: MEDP underperforms 94.74% of its industry peers.
A Quick Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
The Quick ratio of MEDP (0.57) is worse than 92.98% of its industry peers.
MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.22% over the past year.
The Earnings Per Share has been growing by 33.22% on average over the past years. This is a very strong growth
Looking at the last year, MEDP shows a quite strong growth in Revenue. The Revenue has grown by 13.88% in the last year.
MEDP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.62% yearly.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.31% yearly.
Based on estimates for the next years, MEDP will show a quite strong growth in Revenue. The Revenue will grow by 12.31% on average per year.
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
MEDP is valuated quite expensively with a Price/Earnings ratio of 41.61.
MEDP's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.19, MEDP is valued quite expensively.
With a Price/Forward Earnings ratio of 35.39, MEDP can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than 63.16% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of MEDP to the average of the S&P500 Index (23.88), we can say MEDP is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.61 | ||
| Fwd PE | 35.39 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as MEDP.
Based on the Price/Free Cash Flow ratio, MEDP is valued cheaply inside the industry as 80.70% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.77 | ||
| EV/EBITDA | 31.03 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of MEDP may justify a higher PE ratio.
MEDP's earnings are expected to grow with 13.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.13
PEG (5Y)1.25
EPS Next 2Y15.37%
EPS Next 3Y13.97%
5. Dividend
5.1 Amount
MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
595
-5.02 (-0.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.1%
Inst Owner Change0%
Ins Owners0.44%
Ins Owner Change-6.92%
Market Cap16.76B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target550.48 (-7.48%)
Short Float %6.34%
Short Ratio5.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)0.68%
PT rev (3m)27.03%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)11.33%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)5.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)1.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.61 | ||
| Fwd PE | 35.39 | ||
| P/S | 7.11 | ||
| P/FCF | 24.77 | ||
| P/OCF | 23.57 | ||
| P/B | 57.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 31.03 |
EPS(TTM)14.3
EY2.4%
EPS(NY)16.81
Fwd EY2.83%
FCF(TTM)24.02
FCFY4.04%
OCF(TTM)25.25
OCFY4.24%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.13
PEG (5Y)1.25
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 8.4 |
F-Score8
WACC10.94%
ROIC/WACC8.36
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.34%
EBIT Next 3Y15.87%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
Can you provide the valuation status for MEDPACE HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
What is the profitability of MEDP stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?
The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 41.61 and the Price/Book (PB) ratio is 57.08.
How financially healthy is MEDPACE HOLDINGS INC?
The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.